Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
Lancet
; 392(10165): 2718-2727, 2019 12 22.
Article
en En
| MEDLINE
| ID: mdl-30409443
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Vacunas Virales
/
Virus Chikungunya
/
Fiebre Chikungunya
Tipo de estudio:
Clinical_trials
/
Guideline
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Lancet
Año:
2019
Tipo del documento:
Article